News | Robotic Systems | January 21, 2020

First Robotic Coronary Angioplasties Performed With Robocath System in Germany

First robotic PCIs performed at Rheinland Klinikum Neuss Lukaskrankenhaus

Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, performing a PCI using the Robocath R-One robotic catheter guidance system. 

Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, performing a PCI using the Robocath R-One robotic catheter guidance system. 

January 21, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announced it has successfully completed its first robotic coronary angioplasties with its R-One robotic catheter guidance system in Germany. The Percutaneous coronary interventions (PCI) were performed by Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, and his team.

“I’m proud to be the first user of this brand new European robotic solution for PCI in Germany," Haude said. "These robotic interventions pave the way for a new era in interventional cardiology. The benefits brought by R-One are huge for practitioners and will drastically improve our working conditions, which will consequently benefit patient care. My team and I look forward to integrating this robotic-assisted platform for PCI into our day-to-day clinical practice.”

"Professor Haude has over 30 years experience in interventional cardiology and we rely on capitalizing on this kind of experience to develop clinical evidence and demonstrate all the benefits of our solution," said Philippe Bencteux, chairman and founder of Robocath.

These first procedures in Germany are an important strategic step, said Lucien Goffart, CEO of Robocath. He said interest from major industry players is a clear indicator of this, such as the recent purchased of Corindus by Siemens in 2019.
Founded in 2009 by Philippe Bencteux, M.D., Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. Its solutions aim to make medical procedures safer with reliable technologies, while complementing manual interventions.

R-One is the first solution developed by Robocath. It is designed to operate with precision and perform specific movements, creating better interventional conditions. It uses an open architectureto make it compatible with market-leading devices and cath labs. 

The system received European CE mark in February 2019 and started its clinical use in September 2019.

The company hopes to develop a remote treatment system for vascular emergencies.

Watch the VIDEO: First Robotic PCI Case in Germany With Robocath R-One System

For more information: www.robocath.com

 

Related Cath Lab Robot Content:

Siemens Completes Acquisition of Cath Lab Robotics Vendor Corindus

Robocath Successfully Carries Out First Robotic Coronary Angioplasties in Humans

Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System 
 

Related Content

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021